<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04357873</url>
  </required_header>
  <id_info>
    <org_study_id>UC-GMP-1908</org_study_id>
    <secondary_id>2019-003839-33</secondary_id>
    <nct_id>NCT04357873</nct_id>
  </id_info>
  <brief_title>Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations</brief_title>
  <acronym>PEVOsq</acronym>
  <official_title>Phase II Basket Trial Evaluating the Efficacy of a Combination of Pembrolizumab and Vorinostat in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fondation ARC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ERA-NET</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Interventional study evaluating the efficacy of an immunotherapy (pembrolizumab) in&#xD;
      combination with a targeted therapy (vorinostat) in patient with recurrent and/or metastatic&#xD;
      squamous cell carcinoma (localisations : head and neck, lung, cervix, anus, vulva, and penis)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open-label, non-randomized, multi-center, basket phase II trial, evaluating the efficacy of&#xD;
      pembrolizumab in combination with vorinostat in adult patients with recurrent and/or&#xD;
      metastatic squamous cell carcinoma of different locations.&#xD;
&#xD;
      Antitumor activity of the combination will be evaluated using the objective response rate&#xD;
      (ORR) during treatment (investigator assessment).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 28, 2020</start_date>
  <completion_date type="Anticipated">October 2024</completion_date>
  <primary_completion_date type="Anticipated">October 28, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>6 independent cohorts (head and neck, cervix, lung, anus, vulva, and penis) evaluating the association of pembrolizumab and vorinostat</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR), investigator assessment</measure>
    <time_frame>From inclusion to first and subsequent tumor assesment or progression, up to 24 months</time_frame>
    <description>Investigators will assess the ORR. The ORR is defined in each cohort as the percentage of evaluable patients for ORR, designate as the proportion of patients with best response of complete response (CR) or a partial response (PR) during treatment according to response evaluation criteria in solid tumors version 1.1 (RECIST v1.1).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR), central assessment</measure>
    <time_frame>From inclusion to first and subsequent tumor assesment or progression, up to 36 months</time_frame>
    <description>ORR defined as the proportion of patients with best response of CR or PR during treatment, as assessed by a central radiological panel according to RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>immune Objective Response Rate (iORR), central assessment</measure>
    <time_frame>From inclusion to first and subsequent tumor assesment or progression, up to 36 months</time_frame>
    <description>ORR defined as the proportion of patients with best response of CR or PR during treatment, as assessed by a central radiological panel according to immune-specific response criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration Of Response (DOR)</measure>
    <time_frame>From the first assessment of a CR or PR until the date of the first occurrence of PD or death from any cause</time_frame>
    <description>DOR will be evaluated in patients with either CR or PR. DOR is defined as the time from the first assessment of a CR or PR until the date of the first occurrence of progressive disease (PD) or death from any cause (if death occurred within predefined period), whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>From inclusion to disease progression or death, up to 36 months</time_frame>
    <description>PFS is defined per RECIST v1.1 as the time from inclusion until disease progression (per RECIST v1.1) or death from any cause, whichever occurs first. At the time of analysis, a patient alive and without disease progression will be censored at the date of the last tumor assessment. Patients alive without disease progression who started a new anticancer therapy will be censored at the date of the last tumor assessment prior to the start of the new anticancer therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>immune Progression Free Survival (iPFS)</measure>
    <time_frame>From inclusion to disease progression or death, up to 36 months</time_frame>
    <description>iPFS is defined per immune-specific response evaluation criteria in solid tumors (iRECIST) as the time from inclusion until confirmed disease progression (per iRECIST), or death from any cause, whichever occurs first. At the time of analysis, a patient alive and without progression will be censored at the date of the last tumor assessment. Patients alive without disease progression who started a new anti-cancer therapy will be censored at the date of the last tumor assessment prior to the start of the new anticancer therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From inclusion to death from any cause, up to 36 months</time_frame>
    <description>OS is defined as the time from inclusion until death from any cause. Patients who are alive at last follow-up news will be censored at this date.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">111</enrollment>
  <condition>Squamous Cell Lung Cancer</condition>
  <condition>Vulvar Cancer</condition>
  <condition>Penile Cancer</condition>
  <condition>Cervix Cancer</condition>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <condition>Anal Cancer</condition>
  <arm_group>
    <arm_group_label>pembrolizumab + vorinostat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pembrolizumab: 200 mg every 3 weeks, up to 35 administrations&#xD;
Vorinostat: 400 mg once daily, until progression</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pembrolizumab; vorinostat</intervention_name>
    <description>Pembrolizumab: 200 mg every 3 weeks, up to 35 administrations&#xD;
Vorinostat: 400 mg once daily, until progression</description>
    <arm_group_label>pembrolizumab + vorinostat</arm_group_label>
    <other_name>KEYTRUDA; ZOLINZA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged ≥18 years old.&#xD;
&#xD;
          2. Patients with Eastern Cooperative Oncology Group (ECOG) performance status ≤1.&#xD;
&#xD;
          3. Patients must have histologically confirmed recurrent and/or metastatic squamous cell&#xD;
             carcinoma of the head and neck, cervix, lung, anus, vulva, or penis.&#xD;
&#xD;
          4. Patients must have radiologically confirmed progressive recurrent and/or metastatic&#xD;
             disease.&#xD;
&#xD;
          5. Patients naive or previously treated for recurrent and/or metastatic disease for which&#xD;
             a treatment with an anti-PD1/PD-L1 agents and vorinostat is an acceptable option&#xD;
             according to investigator.&#xD;
&#xD;
          6. Disease amenable to biopsy for study purpose.&#xD;
&#xD;
          7. Measurable disease according to RECIST v1.1.&#xD;
&#xD;
          8. Adequate renal function: serum creatinine ≤1.5 x upper limit of normal (ULN) (OR&#xD;
             creatinine clearance [Cockcroft and Gault] ≥30 mL/min for participant with creatinine&#xD;
             levels &gt;1.5 × ULN) within 14 days prior inclusion.&#xD;
&#xD;
          9. Adequate liver function: aspartate aminotransferase (AST) and alanine aminotransferase&#xD;
             (ALT) levels ≤3 × ULN (≤5 ULN when documented liver metastases) and total bilirubin&#xD;
             level ≤1.5 × ULN, within 14 days prior inclusion.&#xD;
&#xD;
         10. Adequate bone marrow function: absolute neutrophil count (ANC) ≥1,000/mm³, platelet&#xD;
             count ≥100,000/mm³, and hemoglobin ≥9 g/dL, within 14 days prior inclusion.&#xD;
&#xD;
         11. Adequate coagulation: prothrombin time (PT)/international normalized ratio (INR) ≤1.5&#xD;
             × ULN within 14 days prior inclusion If participant is receiving anticoagulant therapy&#xD;
             then the PT or activated partial thromboplastin time (aPTT) should be within the&#xD;
             therapeutic range of intended use of anticoagulant.&#xD;
&#xD;
         12. Female of child-bearing potential must have a negative serum pregnancy test within 72&#xD;
             h before starting study treatment.&#xD;
&#xD;
         13. Female of childbearing potential, must use &quot;highly effective&quot; methods of contraception&#xD;
             for the study duration and for 4 months following the last dose of pembrolizumab and 6&#xD;
             months following the last dose of vorinostat.&#xD;
&#xD;
         14. Male participants must agree to use an effective contraceptive for the duration of the&#xD;
             trial and for at least 4 months after the last the last dose of pembrolizumab and 6&#xD;
             months following the last dose of vorinostat (to allow for effective elimination of&#xD;
             the study drugs). Also, they should refrain from donating sperm during this period.&#xD;
&#xD;
         15. Patients must be willing and able to comply with the protocol for the duration of the&#xD;
             study including scheduled visits, treatment plan, and laboratory tests.&#xD;
&#xD;
         16. Patients must be willing and able to comply with other study procedures, including a&#xD;
             baseline tumor biopsy and a series of blood samples throughout the study.&#xD;
&#xD;
         17. Patients able to swallow oral medications.&#xD;
&#xD;
         18. Patients must be affiliated to a Social Security System (or equivalent).&#xD;
&#xD;
         19. Patients must have signed a written informed consent prior to any trial-specific&#xD;
             procedures. When the patient is physically unable to give their written consent, a&#xD;
             trusted person of their choice, independent from the investigator or the sponsor, can&#xD;
             confirm in writing the patient's consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior treatment with anti-PD-1/PD-L1 agents or histone deacetylases (HDAC) inhibitors.&#xD;
&#xD;
          2. Patients with central nervous system involvement that has not been controlled for &gt;3&#xD;
             months.&#xD;
&#xD;
          3. Patients with no other site for biopsy than bone lesions.&#xD;
&#xD;
          4. Patients with other concurrent severe and/or uncontrolled medical disease which could&#xD;
             compromise participation in the study, including uncontrolled diabetes, cardiac&#xD;
             disease, uncontrolled hypertension, congestive cardiac failure, ventricular&#xD;
             arrhythmias, active ischemic heart disease, myocardial infection within one year,&#xD;
             chronic liver or renal disease, active gastrointestinal tract ulceration, severely&#xD;
             impaired lung function.&#xD;
&#xD;
          5. Known history of human immunodeficiency virus (HIV), Hepatitis B virus (HBV; defined&#xD;
             as Hepatitis B surface antigen [HBsAg] reactive) or known active Hepatitis C virus&#xD;
             (HCV; defined as HCV RNA detected) virus infection.&#xD;
&#xD;
          6. History of autoimmune disease with the exception of:&#xD;
&#xD;
               -  (1) Patients with a history of autoimmune hypothyroidism on a stable dose of&#xD;
                  thyroid replacement hormone,&#xD;
&#xD;
               -  (2) Patients with controlled Type 1 diabetes mellitus on a stable insulin&#xD;
                  regimen,&#xD;
&#xD;
               -  (3) Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with&#xD;
                  dermatologic manifestations only (e.g., patients with psoriatic arthritis would&#xD;
                  be excluded) provided that they meet the following conditions: (i) Rash must&#xD;
                  cover less than 10% of body surface area; (ii) Disease is well controlled at&#xD;
                  baseline and only requiring low potency topical steroids; (iii) No acute&#xD;
                  exacerbations of underlying condition within the previous 12 months (not&#xD;
                  requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoid,&#xD;
                  biologic agents, oral calcineurin inhibitors, high-potency or oral steroids).&#xD;
&#xD;
          7. History of allogeneic organ or bone marrow transplantation.&#xD;
&#xD;
          8. History of non-infectious pneumonitis that required steroids or has current&#xD;
             pneumonitis.&#xD;
&#xD;
          9. Has an active infection requiring systemic therapy.&#xD;
&#xD;
         10. Has received a live vaccine within 30 days prior to the first dose of study drug.&#xD;
             Examples of live vaccines include, but are not limited to, the following: measles,&#xD;
             mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus&#xD;
             Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection&#xD;
             are generally killed virus vaccines and are allowed; however, intranasal influenza&#xD;
             vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed.&#xD;
&#xD;
         11. Known prior severe hypersensitivity to investigational products or its excipients,&#xD;
&#xD;
         12. Has received prior systemic anti-cancer therapy including investigational agents&#xD;
             within 4 weeks [could consider shorter interval for kinase inhibitors or other short&#xD;
             half-life drugs] prior to first dose of study treatments.&#xD;
&#xD;
             Note: Participants must have recovered from all adverse events due to previous&#xD;
             therapies to ≤Grade 1 or baseline. Participants with ≤Grade 2 neuropathy may be&#xD;
             eligible.&#xD;
&#xD;
         13. Has received prior radiotherapy within 2 weeks of start of study treatment.&#xD;
             Participants must have recovered from all radiation-related toxicities, not require&#xD;
             corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted&#xD;
             for palliative radiation (≤2 weeks of radiotherapy) to non-central nervous system&#xD;
             disease.&#xD;
&#xD;
         14. Major surgery within 28 days prior to the first dose of study treatments. Note: Local&#xD;
             surgery of isolated lesions for palliative intent is acceptable.&#xD;
&#xD;
         15. Current or prior use of immunosuppressive medication within 7 days before the first&#xD;
             dose of pembrolizumab. The following are exceptions to this criterion:&#xD;
&#xD;
               -  Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra&#xD;
                  articular injection),&#xD;
&#xD;
               -  Systemic corticosteroids at physiologic doses ≤10 mg/day of prednisone or its&#xD;
                  equivalent,&#xD;
&#xD;
               -  Steroids as premedication for hypersensitivity reactions (e.g., CT scan&#xD;
                  premedication).&#xD;
&#xD;
         16. Patients using drugs that could have pharmacokinetics interaction with investigational&#xD;
             drugs. This includes, but is not limited to, valproic acid, coumarin-derivative&#xD;
             anticoagulants, drugs that disrupt electrolyte levels, drugs that may prolong QT.&#xD;
&#xD;
         17. Pregnant women or women who are breast-feeding.&#xD;
&#xD;
         18. Patients enrolled in another therapeutic study within 30 days prior to inclusion and&#xD;
             during the treatment period. Patients can participate in an independent approved&#xD;
             non-interventional studies.&#xD;
&#xD;
         19. Patients unwilling or unable to comply with the medical follow-up required by the&#xD;
             trial because of geographic, familial, social, or psychological reasons.&#xD;
&#xD;
         20. Persons deprived of their liberty or under protective custody or guardianship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christophe Le Tourneau, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Curie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>François Legrand</last_name>
    <phone>017379732</phone>
    <phone_ext>+33</phone_ext>
    <email>f-legrand@unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marta Jimenez</last_name>
    <email>m-jimenez@unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest - Site Paul Papin</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédéric Bigot, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Cousin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elodie Coquan, MD</last_name>
      <phone>02 31 45 50 02</phone>
      <email>coque@baclesse.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xavier Durando</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre George François Leclerc</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François Ghiringhelli</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cyril Abdeddaim</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jérome Lafayette, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurélien Lambert</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest (site René Gauducheau)</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Damien Vansteene</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe Le Tourneau</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud - Hospices Civils de Lyon</name>
      <address>
        <city>Pierre-Bénite</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benoit You</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Godinot</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aude-Marie Savoye</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Borel, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos-Alberto Gomez-Roca</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 20, 2020</study_first_submitted>
  <study_first_submitted_qc>April 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2020</study_first_posted>
  <last_update_submitted>June 16, 2021</last_update_submitted>
  <last_update_submitted_qc>June 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>squamous cell carcinoma</keyword>
  <keyword>squamous cell cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
    <mesh_term>Anus Neoplasms</mesh_term>
    <mesh_term>Vulvar Neoplasms</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Penile Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Vorinostat</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual Participant Data will not be shared at an individual level. Those data will be part of the study database including all enrolled patients.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 14, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/73/NCT04357873/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

